PRNewsWire
15 Jul 2026, 01:41 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
GRAIL's NHS-Galleri Trial failed to achieve its primary endpoint of reducing late-stage cancer diagnoses. — The failure of a primary clinical trial endpoint for a core product typically leads to significant loss of valuation and reduced confidence in the company's technology.
-0.80GRAIL is facing a securities class action lawsuit alleging it misled investors regarding the probability of the NHS-Galleri Trial's success. — Legal proceedings for securities fraud create additional financial liability and reputational risk, further depressing investor sentiment.
-0.40GRAIL experienced a market capitalization loss of over $2.2 billion and a share price drop of over 50% following the trial readout. — This confirms the immediate and severe negative market reaction to the trial failure, establishing a new, lower baseline for the stock.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is facing a securities class action lawsuit after its trial failed to meet its primary endpoint, resulting in a massive loss of market capitalization.
The company is the subject of an investigation into claims for a potential investor class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
